The Latest Cardiac and Vascular News
Mavacamten’s Safety and Efficacy Profile in the PIONEER Study Maintained Through One Year in Open-Label Extension Study of 12 Patients with Symptomatic, Obstructive HCM Evidence Suggests Mavacamten’s Favorable Impact on Cardiac Structure Conference Call Today at 8:30 a.m. ET (5:30 a.m. PT); Data Presentation at American Heart Association Scientific Sessions on Monday, […]
AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of standard of care reduced the incidence of the primary composite endpoint of cardiovascular (CV) death or worsening of HF […]
First Patient Enrolled in DISRUPT CAD IV Clinical Study for Treatment of Severely Calcified Coronary Arteries SANTA CLARA, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that the company […]
Reinforces prior study results demonstrating proportional dose response and that bioavailability of CaPre is not meaningfully affected by the fat content of a meal LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, […]
SAN FRANCISCO, Nov. 6, 2019 /PRNewswire/ — Recardio Inc., a life science company developing regenerative therapies for cardiovascular diseases, announced that it has rolled out its digital platform, CardioCare, throughout Europe to support its future clinical development programs in cardiovascular. Recardio’s Digital Platform CardioCare was awarded and presented at the ESC Conference 2018 and is now […]
– Company to Present Preliminary Data at American Heart Association Scientific Sessions – GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a […]
Novel technology offers physicians first and only real-time detection and monitoring of endovascular bleed complications HOUSTON–(BUSINESS WIRE)–Saranas, Inc. today announced completion of the first U.S. commercial case using the Early Bird® Bleed Monitoring System for real-time detection and monitoring of endovascular bleed complications. Dr. Robert Kipperman, co-director of the Structural Heart […]
Superior TAVI Valve Indicated for All Patients Diagnosed with Aortic Stenosis IRVINE, Calif., Nov. 6, 2019 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark to expand use of the Edwards SAPIEN 3 […]
VANCOUVER, Nov. 01, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that it intends to submit […]
DANVERS, Mass.–(BUSINESS WIRE)–Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist. Ed Soltesz, MD, Mark Anderson, MD, and Danny Ramzy, MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals. Mark […]
